Adenovirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs

Molecular Therapy

Volumn 9, Issue 1, 2004, Pages 67-75

  Whitlock, Paul R ^a   Hackett, Neil R ^a   Leopold, Philip L ^a   Rosengart, Todd K ^b   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Evanston NW Healthcare Medical Group   (United States)

Author keywords

Angiogenesis; Endothelium; Gene therapy; Vascular disease; VEGF

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; COMPLEMENTARY DNA; ISOPROTEIN; RECOMBINANT PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DNA VECTOR; DRUG EFFICACY; GENE EXPRESSION; GENE THERAPY; GENOME ANALYSIS; HYBRID GENE; INTERMETHOD COMPARISON; LIMB ISCHEMIA; MALE; MOUSE; NONHUMAN; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALIA;

EID: 1142299565     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2003.09.014     Document Type: Article

References (72)

1. Black, D. L. (2000). Protein diversity from alternative splicing: a challenge for bioinformatics and post-genome biology. Cell 103: 367-370.
2. Graveley, B. R. (2001). Alternative splicing: increasing diversity in the proteomic world. Trends Genet. 17: 100-107.
3. Smith, C. W., and Valcarcel, J. (2000). Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biochem. Sci. 25: 381-388.
4. Vincenti, V., Cassano, C., Rocchi, M., and Persico, G. (1996). Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93: 1493-1495.
5. Ferrara, N. (2001). Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol Cell Physiol 280: C1358-C1366.
6. Cross, M. J., and Claesson-Welsh, L. (2001). FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22: 201-207.
7. Dvorak, H. F. (2002). Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20: 4368-4380.
8. Campochiaro, P. A. (2000). Retinal and choroidal neovascularization. J. Cell. Physiol. 184: 301-310.
9. Gerber, H. P., et al. (1998). Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273: 30336-30343.
10. Asahara, T., et al. (1999). VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18: 3964-3972.
11. Takeshita, S., et al. (1994). Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 93: 662-670.
12. Isner, J. M., et al. (1994). Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation 91: 2687-2692.
13. Mesri, E. A., Federoff, H. J., and Brownlee, M. (1995). Expression of vascular endothelial growth factor from a defective herpes simplex virus type 1 amplicon vector induces angiogenesis in mice. Circ. Res. 76: 161-167.
14. Muhlhauser, J., et al. (1995). VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ. Res. 77: 1077-1086.
15. Isner, J. M., et al. (1996). Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348: 370-374.
16. Takeshita, S., et al. (1996). Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab. Invest. 75: 487-501.
17. Tsurumi, Y., et al. (1996). Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 94: 3281-3290.
18. Losordo, D. W., et al. (1998). Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98: 2800-2804.
19. Mack, C. A., et al. (1998). Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J. Vasc. Surg. 27: 699-709.
20. Mack, C. A., et al. (1998). Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J. Thoracic. Cardiovosc. Surg. 115: 168-176; discussion 176-177.
21. Taub, P. J., et al. (1999). Locally administered vascular endothelial growth factor cDNA increases survival of ischemic experimental skin flaps. Plast. Reconstr. Surg. 102: 2033-2039.
22. Lazarous, D. F., et al. (1999). Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis. Cardiovasc. Res. 44: 294-302.
23. Rivard, A., et al. (1999). Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am. J. Pathol. 154: 355-363.
24. Rosengart, T. K., et al. (1999). Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann. Surg. 230: 466-470.
25. Rosengart, T. K., et al. (1999). Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100: 468-474.
26. Symes, J. F., et al. (1999). Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann. Thoracic. Surg. 68: 830-836.
27. Tio, R. A., et al. (1999). Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum. Gene Ther. 10: 2953-2960.
28. Gowdak, L. H., Poliakova, L., Li, Z., Grove, R., Lakatta, E. G., and Talan, M. (2000). Induction of angiogenesis by cationic lipid-mediated VEGF165 gene transfer in the rabbit ischemic hindlimb model. J. Vasc. Surg. 32: 343-352.
29. Lee, L. Y., et al. (2000). Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann. Thoracic. Surg. 69: 14-23.
30. Laitinen, M., et al. (2000). Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum. Gene Ther. 11: 263-270.
31. Byun, J., et al. (2000). Efficient expression of the vascular endothelial growth factor gene in vitro and in vivo, using an adeno-associated virus vector. J. Mol. Cell Cardiol. 33: 295-305.
32. Hammond, H. K., and McKirnan, M. D. (2001). Angiogenic gene therapy for heart disease: a review of animal studies and clinical trials. Cardiovasc. Res. 49: 561-567.
33. Huwer, H., et al. (2001). Simultaneous surgical revascularization and angiogenic gene therapy in diffuse coronary artery disease. Eur. J. Cardiothorac. Surg. 20: 1128-1134.
34. Jones, M. K., et al. (2001). Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-1. Gastroenterology 121: 1040-1047.
35. Neumeister, M. W., Song, Y. H., Mowlavi, A., Suchy, H., and Mathur, A. (2001). Effects of liposome-mediated gene transfer of VEGF in ischemic rat gracilis muscle. Microsurgery 21: 58-62.
36. Post, M. J., Laham, R., Sellke, F. W., and Simons, M. (2001). Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc. Res. 49: 522-531.
37. Rajagopalan, S., Shah, M., Luciano, A., Crystal, R., and Nabel, E. G. (2001). Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation 104: 753-755.
38. Sylven, C., et al. (2001). Protein and angiogenic dose - response expression of phVEGFA(165) gene in rat myocardium. J. Thromb. Thrombolysis. 12: 151-156.
39. Sylven, C., et al. (2001). Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris. Coron. Artery Dis. 12: 239-243.
40. Szabo, S., et al. (2001). Gene expression and gene therapy in experimental duodenal ulceration. J. Physiol Paris 95: 325-335.
41. Rasmussen, H. S., Rasmussen, C. S., Macko, J., and Yonehiro, G. (2002). Angiogenic gene therapy strategies for the treatment of cardiovascular disease. Curr. Opin. Mol. Ther. 4: 476-481.
42. Shimpo, M., et al. (2002). AAV-mediated VEGF gene transfer into skeletal muscle stimulates angiogenesis and improves blood flow in a rat hindlimb ischemia model. Cardiovasc. Res. 53: 993-1001.
43. Wright, M. J., Wightman, L. M., Latchman, D. S., and Marber, M. S. (2001). In vivo myocardial gene transfer: optimization and evaluation of intracoronary gene delivery in vivo. Gene Ther. 8: 1833-1839.
44. Leotta, E., et al. (2002). Gene therapy with adenovinus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure. J. Thoracic. Cardiovasc. Surg. 123: 1101-1113.
45. Baumgartner, I., et al. (1998). Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97: 1114-1123.
46. Gowdak, L. H., et al. (2000). Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of schemia. Circulation 102: 565-571.
47. Gurunluoglu, R., Ozer, K., Skugor, B., Lubiatowski, P., Carnevale, K., and Siemionow, M. (2002). Effect of transfection time on the survival of epigastric skin flaps pretreated with adenovirus encoding the VEGF gene. Ann. Plast. Surg. 49: 161-169.
48. Lemstrom, K. B., et al. (2002). Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 105: 2524-2530.
49. Lubiatowski, P., Goldman, C. K., Gurunluoglu, R., Carnevale, K., Siemionow, M. (2002). Enhancement of epigastric skin flap survival by adenovirus-mediated VEGF gene therapy. Plast. Reconstr. Surg. 109: 1986-1993.
50. Lubiatowski, P., Gurunluoglu, R., Goldman, C. K., Skugor, B., Carnevale, K., and Siemionow, M. (2002). Gene therapy by adenovirus-mediated vascular endothelial growth factor and angiopoietin-1 promotes perfusion of muscle flaps. Plast. Reconstr. Surg. 110: 149-159.
51. Romano, D. P., et al. (2002). Adenovirus-mediated VEGF(165) gene transfer enhances wound healing by promoting angiogenesis in CD1 diabetic mice. Gene Ther. 9: 1271-1277.
52. Tischer, E., et al. (1991). The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266: 11947-11954.
53. Bacic, M., Edwards, N. A., and Merrill, M. J. (1995). Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues. Growth Factors 12: 11-15.
54. Jingjing, L., Xue, Y., Agarwal, N., and Roque, R. S. (1999). Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Invest. Ophthalmol. Visual Sci. 40: 752-759.
55. Whittle, C., Gillespie, K., Harrison, R., Mathieson, P. W., and Harper, S. J. (1999). Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. Clin. Sci. 97: 303-312.
56. Poltorak, Z., et al. (1997). VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem. 272: 7151-7158.
57. Whitaker, G. B., Limberg, B. J., and Rosenbaum, J. S. (2001). Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). J. Biol. Chem. 276: 25520- 25531.
58. Park, J. E., Keller, G. A., and Ferrara, N. (1993). The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4: 1317-1326.
59. Cheng, S. Y., Nagane, M., Huang, H. S., and Cavenee, W. K. (1997). Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc. Natl. Acad. Sci. USA 94: 12081-12087.
60. Hersh, J., Crystal, R. G., and Bewig, B. (1995). Modulation of gene expression after replication-deficient, recombinant adenovinus-mediated gene transfer by the product of a second adenovirus vector. Gene Ther. 2: 124-131.
61. Hattori, K., et al. (2001). Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 193: 1005-1014.
62. Rosenfeld, M. A., et al. (1991). Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 252: 431-434.
63. Rosenfeld, M. A., et al. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68: 143-155.
64. Young, C. S. H., Nicolas, A. L., Lu, H., and Munz, P. L. (1999). Methods for creating and analyzing adenovirus vectors that express proteins that act on the viral genome. In Adenovirus Methods and Protocols (W. S. M. Wold, Ed.). Humana Press, Totawa, NJ, pp. 61-83.
65. Zhang, L., et al. (2002). Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells. Biochem. Biophys. Res. Commun. 292: 860-868.
66. Huang, M. T., Gorman, C. M. (1990). Intervening sequences increase efficiency of RNA 3′ processing and accumulation of cytoplasmic RNA. Nucleic Acids Res. 18: 937-947.
67. Korb, M., Ke, Y., and Johnson, L. F. (1993). Stimulation of gene expression by introns: conversion of an inhibitory intron to a stimulatory intron by alteration of the splice donor sequence. Nucleic Acids Res. 21: 5901-5908.
68. Petitclerc, D., et al. (1995). The effect of various introns and transcription terminators on the efficiency of expression vectors in various cultured cell lines and in the mammary gland of transgenic mice. J. Biotechnol. 40: 169-178.
69. Whitelaw, C. B., Archibald, A. L., Harris, S., McClenaghan, M., Simons, J. P., and Clark, A. J. (1991). Targeting expression to the mammary gland: intronic sequences can enhance the efficiency of gene expression in transgenic mice. Transgenic Res. 1: 3-13.
70. Hall, J., Hirst, B. H., Hazlewood, G. P., and Gilbert, H. J. (1992). The use of chimeric gene constructs to express a bacterial endoglucanase in mammalian cells. Biochim. Biophys. Acta 1130: 259-266.
71. Gitay-Goren, H., Soker, S., Vlodavsky, I., and Neufeld, G. (1992). The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem. 267: 6093-6098.
72. Ruhrberg, C., et al. (2002). Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 16: 2684-2698.